Cytokinetics Announces Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics

 

 

 

 

The manuscript, titled “Fast Skeletal Muscle Troponin Activator CK-2066260 Increases Fatigue Resistance by Reducing the Energetic Cost of Muscle Contraction,” was published this month. Cytokinetics conducted the research in collaboration with the laboratory of Professor Håkan Westerblad at the Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. CK-2066260 is a preclinical tool compound of the FSTA class.

Dosing of patients in Phase 2 Trial of SRK-015 in Type 2 and Typ 3 of Spinal Muscular Atrophy

Scholar Rock Announces the Phase 2 clinical trial of SRK-015 in TOPAZ study .

TOPAZ Phase 2 Trial Design

The Phase 2 proof-of-concept trial will evaluate the safety and efficacy of SRK-015 dosed intravenously every four weeks (Q4W) over a 12-month treatment period. The trial is anticipated to enroll approximately 55 patients with Type 2 or Type 3 SMA in the U.S., Canada, and Europe across three distinct and parallel cohorts.

Clinical Trials
NCT03921528